Recent News

• 07.20.2026 - Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02
• 07.13.2026 - Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia
• 06.24.2026 - QA Analyst
• 06.23.2026 - Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02
• 05.13.2026 - Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update
• 05.07.2026 - Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02
• 05.04.2026 - Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"
• 04.27.2026 - Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. to its Board of Directors
• 03.25.2026 - Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results
• 03.19.2026 - Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update

Recent Filings

• 07.20.2026 - 8-K Current report
• 07.20.2026 - 8-K Current report
• 07.20.2026 - EX-99.1 EX-99.1
• 07.14.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.13.2026 - 8-K Current report
• 07.13.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 07.13.2026 - EX-99.1 EX-99.1
• 06.24.2026 - 8-K/A Current report
• 06.23.2026 - 8-K Current report
• 06.23.2026 - EX-99.1 EX-99.1